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Preventative treatment of 
osteoporosis in children with CF 







Poor bone mineral 
density in children 
with CF 
1. Why is it a concern?  
2. How do we minimise 
risk factors 
3. Which risk factors do 
we target and what 
do we aim for? 
Defining CF bone disease and 
osteoporosis 
• The term CF related low bone mineral 
density’ can be applied to children with a  
BMD z score of below -2 
 
• In CF children and adolescents up to the 
age of 20 osteoporosis is defined as 
having a BMI z-score of below -2 and a 
significant fracture history 
Prevalence 
CF Foundation, 2015 





From: Hendriks JJE 
NACFC 2008 
Treatment considerations for preventing 





















Requirements for normal 
bone mineralisation 
Adequate bone mass (especially during the growth 
spurt) 
Protein osteoid formation 
Vitamin D Calcium absorption and 
phosphate utilisation 
Calcium, phosphate and 
Magnesium 
Bone calcification and 
mineralisation 
Vitamin K Carboxylation of osteocalcin 
 Strong evidence that nutritional status predicts 
BMD 
 
 Haworth et al., 1999 and Conway et al., 2000 
BMD significantly correlated with BMI 
 
 Mischler et al., 1979 all patients with low BMD 
were < 5th centile for height 
 
 Fok et al., 2002 BMI percentile position identifies 
those at risk. Aggressive nutritional treatment 






















 Body muscle exerts the largest load and strain  on 
bone and influences size, geometry & density 
 LTM is an independent predictor of bone mass in cystic 
fibrosis (Sermet Gaudelus et al, 2007) 
 Numerous studies have found correlations between 
weight, height, % fat, lean tissue mass, fat free mass 
with a BMD, volumetric BMD and bone mineral 
content  in both adult and paediatric patients 
 
 
 Maximising nutritional status & body muscle mass is                                             




































50% of cases had a reduction in LTM 
White et al., 2014 






Davies et al, 2005 Age (years) 
Normal bone mineral accrual 
● 95% peak bone mass achieved by the end of the   
   pubertal growth spurt 
 
● Bone acquisition is more closely correlated with  
  pubertal stage than with chronological age 
 





Davies et al, 2005 Age (years) 
Suboptimal bone mineral accrual 
 Delayed puberty may retard bone growth & development  
   of peak bone mass 
 Pubertal delay of only 2 years may be very important 
Fracture zone 
Putnam et al, 2015 J Cysts Fibros  








CF Trust Annual data  report, 2013 
 Reduced absorption Lark et al, 2001  
 Inadequate supplementation 
 Non adherence to therapy 
 Reduced stores due to depleted fat mass 
 Reduced sunlight exposure because of illness and medications 
 Low vitamin D binding proteins Speeckaert et al, 2008 
 ? abnormal 1 α hydroxylase in kidney due to renal CFTR  
      Greer et al, 2003 
 Mg deficiency causes functional vitamin D deficiency                              







Canada Grey et al, 2008 88%insufficient 
USA Green et al 2008 46% insufficient 
France Sermet-Gaudelus et al, 
2008 
90% insufficient 
UK Conway et al., 2008 78% insufficient 
15.0% deficient 
Russia Asherova et al, 2008 41.7% insufficient 
16.6% deficient 
Target serum level >20 or >30ng/ml 
(60-75nmol/l) – mixed guidance  
Timing (Possible improved 
absorption with food and enzymes) 
Vitamin D2 or Vitamin D3? - Vitamin 
D3 (Cholecalciferol0l) 
Intervals (no evidence for bolus 
versus daily dosing) 
UV lamps (no recommendation) 
 
Vit D should be measured by total serum 25(OH) 
D as it is associated with health outcomes, is the 
primary circulating form of Vit D and accounts 
for Vit D from diet & sunlight 
 Assess during the winter months (winter levels 
shown to be only 70% of summer values)              
(Barrett  et al, Asherova et al) 
Repeat intervals following changes in treatment 
should be undertaken at 3 months 
 0-1 year - 400-500IU Vitamin D3/day (1ml of 
vitamin preparations 
 <10ng/ml (25nmol/l) urgent management 
 >20<30ng/ml (>50nmol/l<75nmol/l) urgent 
management – and confirmed adherence 
 increase to 800-1000IU Vitamin D3/day by 
Vitamin D only 
 >10 years 800-2000IU/day – increasing to 
1500-6000IU/day 
 32% bone mineral is calcium and 99% is stored in 
bone 
 Peak rates of bone mineralisation 12.5years 
(girls) 14 years (boys) 
 Data from calcium balance studies indicate net 




American Consensus > 9 years 1300-1500mg/day 
 
UK CF trust > 8 years 1300-1500mg/day 
 Calcium intake is a positive predictor of bone 
mineral status in adolescents (Chan et al, 2001)  
 
 Calcium (1000mg) and low dose vitamin D (800IU) 
supplementation resulted in a reduced rate of 
decline in BMD at various sites (non significant). 
There was also a trend towards a reduction in bone 
turnover (Haworth et al, 2004) 
 
 Dietary calcium 
 Calcium supplements 
 High plasma vitamin D to                                





























































Reported Dietary Calcium Intakes in 





























26.7% 39.9% 29.8% 
Suggests that absorption is comparable to healthy children 
 
Lower gut pH in CF may enhance calcium absorption 
 
Adaptive mechanism present when Calcium intake low 
 
Deficiency 
  Sub clinical as assessed by increased PIVKA II- almost 
universal in CF Conway et al, 2005; Rashid et al, 1999; Becker 
et al, 1997; Wilson et al,1997 
 
 Increased % of undercarboxylated osteocalcin (Glu-Oc) 
Fewtrell et al, 2008; Grey et al, 2008; Nicolaidou et al, 2006; 
Conway et al, 2005; Aris et al, 2003  
 
 Associated with increased bone turnover 
 Reduced markers of bone mineral accrual 
 
Most studies support the use of phylloquinone 
  
 
Europe – all pancreatic insufficient patients 
Infants 0.5-2mg/day > 1 year starting dose 1-
10mg/day  (Sermet Gaudelus et al, 2011) 
 
USA 
0.3-0.5mg/day (Aris et al, 2005) 
 
UK   
Babies & infants <2 years 300µg/kg/d 
2-7 yrs   5mg/day  /> 7 yrs   10mg/day (CF Trust, 
2007) 
 
 Dual xray absorptiometry ( 
not volumetric. Areal 
measure g/cm2). DEXA will 
underestimate BMD in small 
individuals with short narrow 
bones and overestimate it 
for larger bones 




 Transmission of sound through the bone is 
measured 
 Speed of sound decreases in osteoporotic bone 
 Low cost, dedicated scanners, acquiring data mostly 
at the bone 
 Dedicated scanners for the calcaneus, phalange and 




(Link ,2012)  
Advantages  QUS 
 
Challenges QUS 
Shown to differentiate those with 
and without fragility fracture and 
to predict fracture  risk 
Doesn’t assess bone quality  
Diverse number of US devices, 
measuring and reporting variable 
bone parameters in  
different ways,  
examining different skeletal sites, 
differing levels of validation data 
for  QUS 
Lack of association with DXA 
measured BMD – has provided 
challenges 
 
Can screen out patients with 
normal bone mass in CF and 
enable selective use of DXA 
(Schepper et al, 2012) 
Not recommended to monitor 
treatment response (ISCD 
guidelines, 2007) 
 
Initial scan age 8-10 years 
Normal LS Z score 
Rescan every 5yrs 
LS Z score -1 to -2 
Rescan every 2yrs 
 
LS Z score <-2 
“CF related low  
  BMD” 
Rescan every yr 
European Cystic Fibrosis Bone Mineralisation Guidelines  
‘If height is ≥1 SD below age and sex matched healthy 
controls, BMD Z scores should be adjusted for height or 
statural age to avoid overestimating deficits in BMD in people 
with short stature’  
Stress the importance of serial height adjusted measurements 
Sermet-Gaudelus et al, 2011 
 BMI, Vitamin D, Vitamin K and calcium play important roles 
in preventing low BMD 
 
 Sensible to normalise the abnormal and correct for known 
risk factors 
 
 The simultaneous presence of a number of factors has made 
it difficult to define the contribution of each 
 
 Longitudinal studies are underway although early studies 




• Aim for 75-150nmol/l                               
(30-60ng/ml) Vit D 
• Aim for 1300-1500mg daily                 




• Aim for 5-10mg/day Vitamin K1 
Aim to achieve minimum of 50th BMI 
percentile (assess dietary energy &protein  
intake annually 
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